Article Contents ::
- 1 The Brand Name ESLIFY Has Generic Salt :: ESLICARBAZEPINE
- 2 ESLIFY Is From Company Torrent Priced :: Rs. 70
- 3 ESLIFY have ESLICARBAZEPINE is comes under Sub class Anti Epileptics of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Epileptics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ESLIFY Has Generic Salt :: ESLICARBAZEPINE
ESLIFY Is From Company Torrent Priced :: Rs. 70
ESLIFY have ESLICARBAZEPINE is comes under Sub class Anti Epileptics of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Epileptics
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Drug Dose ::
Adult: PO: The recommended starting dose is 400 mg once daily which should be increased to 800 mg once daily after one or two weeks. Based on individual response, the dose may be increased to 1,200 mg once daily. Paediatric population The safety and efficacy of eslicarbazepine acetate in children and adolescents below 18 years has not yet been established.
Hypersensitivity to the active substance, to other carboxamide derivatives (e.g. carbamazepine, oxcarbazepine) or to any of the excipients. Second or third degree atrioventricular (AV) block.
Drug Precautions ::
Suicidal ideation Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic active substances in several indications. A meta-analysis of randomised placebo-controlled trials of anti-epileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. Nervous system disorders Eslicarbazepine acetate has been associated with some central nervous system adverse reactions, such as dizziness and somnolence, which could increase the occurrence of accidental injury. Oral contraceptives Eslicarbazepine acetate may decrease the effectiveness of hormonal contraceptives. Additional non-hormonal forms of contraception are recommended Other warnings and precautions If Eslicarbazepine is to be discontinued it is recommended to withdraw it gradually to minimise the potential of increased seizure frequency. Concomitant use of eslicarbazepine acetate with oxcarbazepine is not recommended because this may cause overexposure to the active metabolites. Hyponatraemia Hyponatraemia has been reported as an adverse reaction in 1.2% of patients treated with Eslicarbazepine. Hyponatraemia is asymptomatic in most cases, however, it may be accompanied by clinical symptoms like worsening of seizures, confusion, decreased consciousness. Frequency of hyponatraemia increased with increasing eslicarbazepine acetate dose. In patients with pre-existing renal disease leading to hyponatraemia, or in patients concomitantly treated with medicinal products which may themselves lead to hyponatraemia (e.g. diuretics, desmopressin, carbamazepine), serum sodium levels should be examined before and during treatment with eslicarbazepine acetate. Furthermore, serum sodium levels should be determined if clinical signs of hyponatraemia occur. Apart from this, sodium levels should be determined during routine laboratory examination. If clinically-relevant hyponatraemia develops, eslicarbazepine acetate should be discontinued. PR interval Prolongations in PR interval have been observed in clinical studies with eslicarbazepine acetate. Caution should be exercised in patients with medical conditions (e.g. low levels of thyroxine, cardiac conduction abnormalities), or when taking concomitant medicinal products known to be associated with PR prolongation. Renal impairment Caution should be exercised in the treatment of patients with renal impairment and the dose should be adjusted according to creatinine clearance. In patients with CLCR <30 ml/min use is not recommended due to insufficient data. Hepatic impairment As clinical data are limited in patients with mild to moderate hepatic impairment and pharmacokinetic and clinical data are missing in patients with severe hepatic impairment, eslicarbazepine acetate should be used with caution in patients with mild to moderate hepatic impairment and is not recommended in patients with severe hepatic impairment. Drug Side Effects ::
Allergic reactions: May cause serious skin rash or other serious allergic reactions Very common (may affect more than 1 in 10 people) side effects are: • Feeling dizzy or sleepy. Common (may affect up to 1 in 10 people) side effects are: • Feeling unsteady or having a sensation of spinning or floating; • Feeling sick or vomiting; • Headache; • Diarrhoea; • Seeing double or blurred vision; • Difficulty in concentration; • Feeling low in energy or tired; • Shaking; • Skin rash; • Blood tests showing that you have low levels of sodium in your blood; • Decrease of appetite; • Difficulty in sleeping; • Difficulty in coordinating movements (ataxia).
Pregnancy category ::
Drug Mode of Action ::
Antiepileptic drug; eslicarbazepine acetate is a prodrug that is activated to eslicarbazepine (S-licarbazepine), the major active metabolite of oxcarbazepine. Stabilizes neuronal membranes by blocking Na+ channels; this may inhibit repetitive firing and may decrease the propagation of synaptic impulses; may also increase potassium conductance and modulate the activity of high-voltage activated calcium channels.
Drug Interactions ::